{"id":59262,"date":"2021-03-04T16:35:27","date_gmt":"2021-03-04T21:35:27","guid":{"rendered":"https:\/\/rarediseases.org\/new-report-finds-medical-treatments-for-rare-diseases-account-for-only-11-of-us-drug-spending-nearly-80-of-orphan-products-treat-rare-diseases-exclusively\/"},"modified":"2021-03-04T16:35:27","modified_gmt":"2021-03-04T21:35:27","slug":"new-report-finds-medical-treatments-for-rare-diseases-account-for-only-11-of-us-drug-spending-nearly-80-of-orphan-products-treat-rare-diseases-exclusively","status":"publish","type":"post","link":"https:\/\/rarediseases.org\/es\/new-report-finds-medical-treatments-for-rare-diseases-account-for-only-11-of-us-drug-spending-nearly-80-of-orphan-products-treat-rare-diseases-exclusively\/","title":{"rendered":"New Report Finds Medical Treatments for Rare Diseases Account for Only 11% of US Drug Spending; Nearly 80% of Orphan Products Treat Rare Diseases Exclusively"},"content":{"rendered":"

Washington, DC, March 4, 2021<\/span><\/b>\u2014As US policymakers<\/span>\u00a0consider options to address rising health care costs while still meeting the needs of patients,\u00a0<\/span>a new report from IQVIA has found that\u00a0rare diseases account for just\u00a0<\/span>11% of medical invoice spending in the United States, and 79% of all orphan products treat only rare diseases. The report also highlights recent progress in drug development that has resulted in more people<\/span>\u00a0with rare diseases having access to critical treatments.<\/span>\u00a0<\/span><\/p>\n

As of January 1, 2020, 564 orphan products were approved by the US Food and Drug Administration (FDA) to treat 838 rare diseases (or \u201cindications\u201d). Thirty percent of all orphan indications<\/span>\u00a0were approved in the three years prior to the study, which is based on 2019 data. Multiple uses for the same medicine have become increasingly common, particularly in cancer and autoimmune diseases, as improved understanding of biological pathways allows for a<\/span>\u00a0single therapy to treat numerous rare and common conditions. Still, most orphan products treat only one rare disease.<\/span>\u00a0<\/span><\/p>\n

The report also demonstrates that patients are gaining access to multiple treatment options due to generics and biosimilars entering the market, in many cases, even when there is a term of orphan drug exclusivity in effect.<\/span>\u00a0<\/span><\/p>\n

\u201cDrug pricing is an issue that affects every American. Our hope is for this data to raise awareness of the critical need for new rare disease\u00a0<\/span>treatments, and<\/span>\u00a0demonstrate that the overall amount spent on those treatments is small compared to the total drug\u00a0<\/span>spend in the United States,\u201d said Peter L. Saltonstall, President and CEO of the National Organization for Rare Disorders (NORD\u00ae). \u201cPeople with rare diseases need help, and the Orphan Drug Act is important for s<\/span>purring innovation.\u201d<\/span>\u00a0<\/span><\/p>\n

Since 2010, the share of orphan drug spending has increased by five percentage points, likely due to the increasing number of approved orphan products. During this same time, specialty drug spending has also risen by 22 percentage points and now accounts for 4<\/span>7% of all medical invoice spending. However, specialty drugs and orphan drugs are not the same, and IQVIA found 77% of specialty drug spending is for the treatment of common conditions and not rare diseases.<\/span>\u00a0<\/span><\/p>\n

Approximately 7,000 known rare diseases affect more than 25 million Americans. Rare diseases tend to be chronic, serious and life-threatening. Approximately 80% of rare diseases are genetic in origin. More than 9<\/span>0% of rare diseases have no treatment.<\/span>\u00a0<\/span><\/p>\n

The report, \u201cOrphan Drugs in the United States: Rare Disease Innovation and Cost Trends Through 2019,\u201d is available at\u00a0<\/span>rarediseases.org\/rareinsights<\/span><\/a>.<\/span>\u00a0NORD commissions the study every two years to examine the state of drug development for rare diseases as part of its mission to support people with rare diseases.<\/span>\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

Washington, DC, March 4, 2021\u2014As US policymakers\u00a0consider options to address rising health care costs while still meeting the needs of patients,\u00a0a new report from IQVIA has found that\u00a0rare diseases account … <\/p>\n

Continue reading \u00abNew Report Finds Medical Treatments for Rare Diseases Account for Only 11% of US Drug Spending; Nearly 80% of Orphan Products Treat Rare Diseases Exclusively\u00bb<\/span><\/a><\/p>\n","protected":false},"author":47,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","_price":"","_stock":"","_tribe_ticket_header":"","_tribe_default_ticket_provider":"","_tribe_ticket_capacity":"","_ticket_start_date":"","_ticket_end_date":"","_tribe_ticket_show_description":"","_tribe_ticket_show_not_going":false,"_tribe_ticket_use_global_stock":"","_tribe_ticket_global_stock_level":"","_global_stock_mode":"","_global_stock_cap":"","_tribe_rsvp_for_event":"","_tribe_ticket_going_count":"","_tribe_ticket_not_going_count":"","_tribe_tickets_list":"[]","_tribe_ticket_has_attendee_info_fields":false,"footnotes":""},"categories":[190,210,504,193],"tags":[2718,398,244,2720,1788,1278,225,263,2719,199,1086,1623,2717,2032],"class_list":["post-59262","post","type-post","status-publish","format-standard","hentry","category-featured-news","category-industry","category-press-releases","category-research","tag-biological-pathways","tag-biosimilars","tag-fda","tag-generics","tag-iqvia-institute","tag-national-organization-for-rare-disorders","tag-nord","tag-orphan-drugs","tag-orphan-drugs-in-the-united-states-rare-disease-innovation-and-cost-trends-through-2019","tag-orphan-products","tag-prescription-drug-spending","tag-rareinsights","tag-specialty-drug-spending","tag-us-food-and-drug-administration"],"acf":[],"_links":{"self":[{"href":"https:\/\/rarediseases.org\/es\/wp-json\/wp\/v2\/posts\/59262","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rarediseases.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/rarediseases.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/rarediseases.org\/es\/wp-json\/wp\/v2\/users\/47"}],"replies":[{"embeddable":true,"href":"https:\/\/rarediseases.org\/es\/wp-json\/wp\/v2\/comments?post=59262"}],"version-history":[{"count":0,"href":"https:\/\/rarediseases.org\/es\/wp-json\/wp\/v2\/posts\/59262\/revisions"}],"wp:attachment":[{"href":"https:\/\/rarediseases.org\/es\/wp-json\/wp\/v2\/media?parent=59262"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rarediseases.org\/es\/wp-json\/wp\/v2\/categories?post=59262"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rarediseases.org\/es\/wp-json\/wp\/v2\/tags?post=59262"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}